Experienced in Dysembryoplastic Neuroepithelial Tumors (DNET)

Ann Hoeben

Maastricht, LI, NL 
Experienced in Dysembryoplastic Neuroepithelial Tumors (DNET)
Maastricht, LI, NL 
OverviewLocationsClinical Research

Overview

Ann Hoeben practices in Maastricht, Netherlands. Ms. Hoeben is rated as an Experienced expert by MediFind in the treatment of Dysembryoplastic Neuroepithelial Tumors (DNET). Her top areas of expertise are Glioblastoma, Astrocytoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Glioma, and Gastrostomy.

Her clinical research consists of co-authoring 77 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Dysembryoplastic Neuroepithelial Tumors (DNET).

Gender
Female

Locations

Maastricht, LI, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase III Trial of Marizomib in Combination With Standard Temozolomide-based Radiochemotherapy Versus Standard Temozolomide-based Radiochemotherapy Alone in Patients With Newly Diagnosed Glioblastoma
A Phase III Trial of Marizomib in Combination With Standard Temozolomide-based Radiochemotherapy Versus Standard Temozolomide-based Radiochemotherapy Alone in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Completed
Publish Date: July 01, 2025
Intervention Type: Drug, Radiation
Study Drugs: Marizomib, Temozolomide
Study Phase: Phase 3
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Terminated
Publish Date: July 10, 2024
Intervention Type: Drug
Study Drugs: Feladilimab, Pembrolizumab
Study Phase: Phase 3
View 1 Less Clinical Trial

77 Total Publications

A Proposal for HPV-Associated Oropharyngeal Carcinoma in the Ninth Edition Clinical TNM Classification.
A Proposal for HPV-Associated Oropharyngeal Carcinoma in the Ninth Edition Clinical TNM Classification.
Journal: JAMA otolaryngology-- head & neck surgery
Published: May 08, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Hoeben's expertise for a condition
ConditionClose
      View All 7 Advanced Conditions
      View All 15 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile